 | Lotus Mallbris |
Prominent publications by Lotus Mallbris
BACKGROUND: Two phase 3 trials (UNCOVER-2 and UNCOVER-3) showed that at 12 weeks of treatment, ixekizumab, a monoclonal antibody against interleukin-17A, was superior to placebo and etanercept in the treatment of moderate-to-severe psoriasis. We report the 60-week data from the UNCOVER-2 and UNCOVER-3 trials, as well as 12-week and 60-week data from a third phase 3 trial, UNCOVER-1.
METHODS: We randomly assigned 1296 patients in the UNCOVER-1 trial, 1224 patients in the UNCOVER-2 trial, ...
| Known for 3 Trials | Ixekizumab Placebo | Week Patients | Spga Score | Starting Dose |
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that is being investigated for psoriasis. Psoriasis impacts on physical and psychological well-being; improvements in health-related quality of life (HRQoL) with etanercept in psoriasis are well documented.
OBJECTIVE: To evaluate HRQoL with tofacitinib, vs. placebo or etanercept, in the Phase 3, randomized, placebo-controlled, non-inferiority, Oral-treatment Psoriasis Trial (OPT) Compare Study (NCT01241591).
METHODS: Adults with ...
| Known for Tofacitinib Placebo | 10 Bid | Phase 3 Study | Plaque Psoriasis | Dlqi Score |
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor being investigated for psoriasis.
OBJECTIVES: We sought to report longer-term tofacitinib efficacy and safety in patients with moderate to severe psoriasis.
METHODS: Data from 2 identical phase-III studies, Oral-treatment Psoriasis Trial Pivotal 1 and 2, were pooled with data from these patients in an ongoing open-label long-term extension study. Patients (n = 1861) were randomized 2:2:1 to tofacitinib 5 mg, 10 mg, or placebo ...
| Known for Patients Tofacitinib | Janus Kinase | 10 Bid | 2 Randomized | Phase Iii |
Tofacitinib withdrawal and retreatment in moderate‐to‐severe chronic plaque psoriasis: a randomized controlled trial
[ PUBLICATION ]
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor being investigated for the treatment of moderate-to-severe plaque psoriasis.
OBJECTIVES: To compare outcomes following tofacitinib withdrawal with outcomes of continuation.
METHODS: In this phase 3 study (NCT01186744), patients received tofacitinib 5 mg (n = 331) or 10 mg (n = 335) twice daily for 24 weeks. The patients who achieved both ≥ 75% reduction in Psoriasis Area and Severity Index (PASI 75) score from baseline and ...
| Known for Tofacitinib Withdrawal | Pga Responses Patients | Chronic Plaque | Initial Treatment | 5 10 |
IMPORTANCE: Psoriasis, psoriatic arthritis, and uveitis are inflammatory disorders with significant overlap in their inflammatory pathways. Limited evidence is available about the relationship between psoriatic disease and uveitis.
OBJECTIVE: To investigate the potential bidirectional relationship between psoriatic disease, including psoriasis and psoriatic arthritis, and uveitis.
DESIGN, SETTING, AND PARTICIPANTS: We performed a nationwide cohort study of the Danish population from ...
| Known for Psoriatic Disease | Patients Psoriasis | Arthritis Uveitis | Nationwide Cohort | Bidirectional Association |
BackgroundPatients with psoriasis who have an inadequate response to one biologic may benefit from switching to a new biologic, such as ixekizumab, a high affinity monoclonal antibody that selectively targets interleukin (IL)-17A.ObjectiveOur aim was to assess the response to ixekizumab in patients with moderate-to-severe plaque psoriasis who did not respond adequately to etanercept using a post-hoc analysis in two phase III studies.MethodsFor the subanalyses in two phase III trials ...
| Known for 12 Weeks | Ixekizumab Patients | Phase Iii | Plaque Psoriasis | Treatment Failure |
BACKGROUND: Head-to-head randomized studies comparing ixekizumab and secukinumab in the treatment of psoriasis are not available.
OBJECTIVES: To assess efficacy and quality of life using matching-adjusted indirect comparisons for treatment with ixekizumab vs. secukinumab.
METHODS: Psoriasis Area and Severity Index (PASI) improvement of at least 75%, 90% and 100% and Dermatology Life Quality Index (DLQI) 0/1 response rates for approved dosages of ixekizumab (160 mg at Week 0, then 80 mg ...
| Known for Plaque Psoriasis | Indirect Comparison | Ixekizumab Secukinumab | Monoclonal Antibodies | Pasi 75 |
BACKGROUND: Biologics are effective for the treatment of psoriasis. However, treatment outcomes may differ among biologic-naive patients and those switched from previous biological therapies.
OBJECTIVES: The study's objective was to investigate efficacy and safety of ixekizumab, a high-affinity anti-interleukin-17A antibody, in patients with psoriasis with and without previous exposure to biologics.
METHODS: Data were integrated from the 12-week induction phase of two ...
| Known for Phase Iii | Ixekizumab Patients | Integrated Analysis | Previous Exposure | Biological Therapies |
BACKGROUND: The efficacy of ixekizumab, an anti-interleukin-17A (anti-IL-17A) monoclonal IgG4 antibody, was demonstrated in moderate-to-severe psoriasis patients when administered via prefilled syringe (PFS).
OBJECTIVE: To evaluate the effect of two drug delivery devices on the pharmacokinetics (PK) of ixekizumab as well as efficacy and safety with both devices.
METHODS: In the first 12 weeks of an open-label, phase 3 study, moderate-to-severe psoriasis patients were randomized to ...
| Known for Safety Ixekizumab | Subcutaneous Administration | 12 Weeks | Prefilled Syringe | Autoinjector Patients |
BACKGROUND: Despite unmet need, 15 years have passed since a topical therapy with a new mechanism of action for atopic dermatitis (AD) has been approved. Janus kinase (JAK) inhibitor treatment effect via topical application in patients with AD is unknown.
OBJECTIVES: Tofacitinib, a small-molecule JAK inhibitor, was investigated for the topical treatment of AD.
METHODS: In this 4-week, phase IIa, randomized, double-blind, vehicle-controlled study (NCT02001181), 69 adults with ...
| Known for Topical Tofacitinib | Atopic Dermatitis | Cfb Week | Protein Kinase Inhibitors | 15 Years |
Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study
[ PUBLICATION ]
BACKGROUND: Psoriasis, Crohn disease (CD) and ulcerative colitis (UC) are chronic inflammatory disorders with overlapping genetic architecture. However, data on the frequency and risk of CD and UC in psoriasis are scarce and poorly understood.
OBJECTIVES: To investigate the association between CD and UC in patients with psoriasis.
METHODS: All Danish individuals aged ≥ 18 years between 1 January 1997 and 31 December 2012 were linked in nationwide registers. Psoriasis severity was defined ...
| Known for Uc Psoriasis | Inflammatory Bowel Disease | Psoriatic Arthritis | Ulcerative Colitis | 1 January |
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated data
[ PUBLICATION ]
BACKGROUND: Safety of biologics is important when treating patients with psoriasis.
OBJECTIVE: We sought to determine the safety of ixekizumab in psoriasis.
METHODS: Integrated safety data are presented from a 12-week induction period, a 12- to 60-week maintenance period, and from all ixekizumab-treated patients from 7 clinical trials. Exposure-adjusted incidence rates (IRs) per 100 patient-years are reported.
RESULTS: Overall, 4209 patients received ixekizumab (total exposure: 6480 ...
| Known for Ixekizumab Psoriasis | Induction Period | Term Safety | Adult Antibodies Monoclonal | Treatmentemergent Aes |
BACKGROUND: Infections are associated with biological therapies in psoriasis.
OBJECTIVES: To summarize the incidence of infections in patients with moderate-to-severe psoriasis treated with ixekizumab, an anti-interleukin-17A monoclonal antibody.
METHODS: Infections are summarized from an integrated database of seven controlled and uncontrolled ixekizumab psoriasis trials. Data are presented from placebo-controlled induction (weeks 0-12; UNCOVER-1, UNCOVER-2 and UNCOVER-3) and ...
| Known for Ixekizumab Patients | Monoclonal Antibody | Biological Therapies | Incidence Rates | 12 Weeks |
Pruritus and quality of life in moderate‐to‐severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study
[ PUBLICATION ]
BACKGROUND: Pruritus is a clinically important symptom of psoriasis that has a major impact on quality of life (QoL).
OBJECTIVE: The objective of this study was to examine pruritus and QoL in patients with moderate-to-severe psoriasis treated with etanercept (ETN) in the PRISTINE clinical trial.
METHODS: Patients were randomized (1 : 1, double-blind) to ETN 50 mg QW or 50 mg BIW for 12 weeks, followed by 50 mg QW for 12 weeks. Pruritus was reported as 0 (no itching) to 5 (severe ...
| Known for Plaque Psoriasis | Week Patients | Pruritus Quality | Life Qol | Anxiety Depression |
BACKGROUND: Tofacitinib is an oral Janus kinase (JAK) inhibitor. Immunomodulatory therapies can increase the risk for herpes zoster (HZ) in patients with psoriasis.
OBJECTIVE: To evaluate the relationship between tofacitinib use and HZ risk.
METHODS: We used phases 2 and 3 and long-term extension (LTE) data from the tofacitinib development program in psoriasis to calculate HZ incidence rates (IR; events per 100 patient-years); potential HZ risk factors were evaluated using ...
| Known for Herpes Zoster | Patients Tofacitinib | Hz Risk | Immunomodulatory Therapies | Oral Janus Kinase |
Lotus Mallbris: Influence Statistics
| Concept | World rank |
|---|---|
| swedish patients hae | #1 |
| stg single | #1 |
| ixekizumab uncover1 | #1 |
| associate psoriasis | #1 |
| stg psors1 | #1 |
| today hae | #1 |
| hae eq5d | #1 |
| guttate phenotype | #1 |
| variant psoriasis | #1 |
| weeks uncover1 | #1 |
| psoriasis swedish population | #1 |
| eq5d hae attack | #1 |
| psoriasis cardiovascularrelated parameters | #1 |
| eq5d attack | #1 |
| stg publication cell | #1 |
| patients cardiovascularrelated parameters | #1 |
| stg psoriasis | #1 |
| stg sequence variants | #1 |
| hae swedish patients | #1 |
| sweden hereditary | #1 |
| induction period weeks | #1 |
| onset plaque psoriasis | #1 |
| uncover3 week | #1 |
| eq5d today | #1 |
| opt retreatment | #1 |
| ixekizumab maintenance period | #1 |
| efficacy ixekizumab | #1 |
| opt compare | #1 |
| pharmacokinetics ixekizumab | #1 |
| hlacw0602 status | #1 |
| ixekizumab integrated | #1 |
| attack eq5d | #1 |
| cardiovascularrelated parameters patients | #1 |
| 60 uncover1 | #1 |
| swedish population psoriasis | #1 |
| biologics study | #1 |
| uncover2 ixekizumab | #1 |
| disease stg | #1 |
| ixekizumab maintenance | #1 |
| eq5d today score | #1 |
| psoriasissusceptibility region | #1 |
| sarcoidosis responding | #1 |
| psoriasis scarce | #1 |
| eq5d hae | #1 |
Key People For Psoriatic Arthritis
Lotus Mallbris:Expert Impact
Concepts for whichLotus Mallbrishas direct influence:Psoriatic arthritis, Patients psoriasis, Facial psoriasis, Plaque psoriasis, Patients tofacitinib, Ixekizumab treatment, Hereditary angioedema, Psoriasis patients.
Lotus Mallbris:KOL impact
Concepts related to the work of other authors for whichfor which Lotus Mallbris has influence:Psoriatic arthritis, Atopic dermatitis, Patients psoriasis, Metabolic syndrome, Hidradenitis suppurativa, Janus kinase, Hereditary angioedema.
Tools
Is this your profile? Claim your profile Copy URL Embed Link to your profile |